Clinical trial
Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With…
NCT00142480 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00142480 |
|---|---|
| Title | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer |
| Official title | Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Industry Sanofi-Synthelabo Hoffmann-La Roche |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Biliary Tract Cancer, Gallbladder Adenocarcinoma |
| Intervention type | Drug, Procedure |
| Interventions | Capecitabine, Oxaliplatin, Bevacizumab, Radiation therapy |
| Enrollment | 8 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Apr 1, 2011 |
| First posted | Sep 2, 2005 |
| Last update posted | Apr 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: